Review Article

The Role of Nrf2-Mediated Pathway in Cardiac Remodeling and Heart Failure

Table 1

Activation of Nrf2 and its downstream genes to treat cardiac remodeling and HF.

NameTarget disease modelSpeciesFunctionWays and volumeReferences

Nrf2 activators SulforaphaneIschemia (I/R, Langendorff)SD ratsPrevent cardiac apoptosis0.5 mg/kg/d, 3 days, IP[102]
Diabetes (type 1, STZ)MicePrevent cardiac hypertrophy, fibrosis, and apoptosis0.5 mg/kg/d, 3 months, IP[103]
MG132Hypertension (abdominal aortic banding)SD ratsPrevent cardiac hypertrophy and fibrosis0.1 mg/kg/d, 8 or 16 weeks, IP[104, 105]
Diabetes (type 1, OVE)MicePrevent cardiac hypertrophy and apoptosis10  g/kg/d, 3 months, IP[106]
ResveratrolIschemia (MI, LAD occlusion)SD ratsImprove cardiac stem cells’ survival, proliferation, and differentiation2.5 mg/kg/d, 2 weeks, gavage[107]
AllicinHypertension (Ang II)SD ratsPrevent cardiac hypertrophy and fibrosis180 mg/kg/d, 8 weeks, receiving a diet in addition to standard chow[108]
α-Lipoic acidIschemia (I/R, coronary artery ligation followed by reperfusion)SD ratsPrevent cardiac apoptosis15 mg/kg, one time, IV[79]
Hydrogen sulfateIschemia (I/R, coronary artery ligation followed by reperfusion)MicePrevent cardiac apoptosis0.1 mg/kg, one time, IV[109]
4-HNEIschemia (MI, Langendorff)MiceImprove cardiac function4 mg/kg, one time, IV[110]
HO-1 activators CoPPHypertension (Ang II)Wistar ratsPrevent cardiac hypertrophy1 mg/kg, every 2 days, 2 weeks, IP[25]
Hypertension plus ischemia (spontaneous hypertensive rats + LAD occlusion)Wistar ratsPrevent cardiac hypertrophy4.5 mg/kg, one/week, 6 weeks, IP[111]
HeminIschemia (MI, LAD occlusion)SD ratsPrevent cardiac apoptosis4 mg/kg, every 2 days, 4 weeks, IP[112]
SOD activatorsEUK-8Hypertension (transverse aortic banding)MicePrevent cardiac hypertrophy, fibrosis, and apoptosis25 mg/kg/d, 4 weeks, IP[113]
N-AcetylcysteineDiabetes (STZ)Wistar ratsImprove cardiac function1.4-1.5 g/kg/d, 8 weeks, in drinking water[114]